EA008056B1 - Противораковые комбинации - Google Patents

Противораковые комбинации Download PDF

Info

Publication number
EA008056B1
EA008056B1 EA200400370A EA200400370A EA008056B1 EA 008056 B1 EA008056 B1 EA 008056B1 EA 200400370 A EA200400370 A EA 200400370A EA 200400370 A EA200400370 A EA 200400370A EA 008056 B1 EA008056 B1 EA 008056B1
Authority
EA
Eurasian Patent Office
Prior art keywords
topoisomerase
inhibitors
pharmaceutically acceptable
compound selected
acceptable salt
Prior art date
Application number
EA200400370A
Other languages
English (en)
Russian (ru)
Other versions
EA200400370A1 (ru
Inventor
Уилльям Роберт Уилсон
Бронуин Гей Сиим
Original Assignee
Кэнсе Рисёч Текнолоджи Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кэнсе Рисёч Текнолоджи Лимитед filed Critical Кэнсе Рисёч Текнолоджи Лимитед
Publication of EA200400370A1 publication Critical patent/EA200400370A1/ru
Publication of EA008056B1 publication Critical patent/EA008056B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
EA200400370A 2001-09-03 2002-09-03 Противораковые комбинации EA008056B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0121285.1A GB0121285D0 (en) 2001-09-03 2001-09-03 Anti-cancer combinations
PCT/GB2002/004025 WO2003020259A2 (en) 2001-09-03 2002-09-03 Combinations of dmxaa and other anti-cancer agents

Publications (2)

Publication Number Publication Date
EA200400370A1 EA200400370A1 (ru) 2004-08-26
EA008056B1 true EA008056B1 (ru) 2007-02-27

Family

ID=9921418

Family Applications (3)

Application Number Title Priority Date Filing Date
EA200400370A EA008056B1 (ru) 2001-09-03 2002-09-03 Противораковые комбинации
EA200601118A EA010857B1 (ru) 2001-09-03 2002-09-03 Способ лечения рака, применение dmxaa в противораковых комбинациях, способ их получения и набор
EA200801611A EA200801611A1 (ru) 2001-09-03 2002-09-03 Противораковые комбинации

Family Applications After (2)

Application Number Title Priority Date Filing Date
EA200601118A EA010857B1 (ru) 2001-09-03 2002-09-03 Способ лечения рака, применение dmxaa в противораковых комбинациях, способ их получения и набор
EA200801611A EA200801611A1 (ru) 2001-09-03 2002-09-03 Противораковые комбинации

Country Status (23)

Country Link
US (6) US7863322B2 (enExample)
EP (3) EP1423105B9 (enExample)
JP (3) JP2005509599A (enExample)
CN (5) CN101596186A (enExample)
AT (1) ATE415963T1 (enExample)
AU (1) AU2002324143B2 (enExample)
BR (1) BR0212258A (enExample)
CA (1) CA2458459A1 (enExample)
CY (1) CY1110426T1 (enExample)
DE (1) DE60230159D1 (enExample)
DK (1) DK1423105T3 (enExample)
EA (3) EA008056B1 (enExample)
ES (1) ES2321283T3 (enExample)
GB (1) GB0121285D0 (enExample)
IL (1) IL160178A0 (enExample)
IS (1) IS7144A (enExample)
MX (1) MXPA04002004A (enExample)
NO (1) NO20040591L (enExample)
NZ (5) NZ567456A (enExample)
PT (1) PT1423105E (enExample)
SI (1) SI1423105T1 (enExample)
WO (1) WO2003020259A2 (enExample)
ZA (1) ZA200401078B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2619335C2 (ru) * 2012-01-20 2017-05-15 Исофол Медикал Аб Тетрагидрофолаты в комбинации с ингибиторами egfr

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
JP4638098B2 (ja) * 1999-06-14 2011-02-23 キャンサー・リサーチ・テクノロジー・リミテッド 癌治療
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
EP1311262A4 (en) 2000-07-28 2005-06-01 Cancer Rec Tech Ltd COMBINED TREATMENT AGAINST CANCER
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB2386836B (en) * 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
GB0321999D0 (en) * 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations
PT1689404E (pt) 2003-11-13 2008-12-15 Pharma Mar Sau Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro
DK1658848T3 (da) 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid
AU2006283371A1 (en) * 2005-08-26 2007-03-01 Antisoma Research Limited Combinations comprising DMXAA for the treatment of cancer
GB0517387D0 (en) * 2005-08-26 2005-10-05 Antisoma Res Ltd Combinations for the treatment of cancer
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
JP2011506455A (ja) * 2007-12-13 2011-03-03 ノバルティス アーゲー 癌を処置するための治療薬の組み合わせ剤
CN101279967B (zh) * 2008-05-29 2010-11-10 武汉远大制药集团有限公司 一种治疗癌症的三甲基呫吨酮-4-乙酸药物组合物及其用途
EP2927240A1 (en) 2008-08-25 2015-10-07 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
US20100068302A1 (en) * 2008-09-17 2010-03-18 Traslational Cancer Drugs Pharma, S.L. Methods and compositions for the treatment of cancer
EP2464347A1 (en) * 2009-08-11 2012-06-20 Novartis AG Combinations of vascular disrupting agents with inhibitor of apoptosis proteins antagonists
WO2011160063A2 (en) 2010-06-18 2011-12-22 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
ES2704303T3 (es) 2010-08-24 2019-03-15 Dana Farber Cancer Inst Inc Procedimientos para la predicción de una respuesta contra el cáncer
CN105906602B (zh) * 2011-05-16 2018-07-10 杭州民生药物研究院有限公司 2-(5,6-二甲基呫吨酮-4-基)-乙酸衍生物的制备方法
CA2839210A1 (en) 2011-06-17 2012-12-20 Myriad Genetics, Inc. Methods and materials for assessing allelic imbalance
EP3660161B1 (en) 2011-12-21 2024-07-31 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
EP3415915B1 (en) 2012-02-23 2024-10-23 Children's Medical Center Corporation Methods for predicting response to parp inhibitors
CA2867434C (en) 2012-06-07 2021-10-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
US10308986B2 (en) 2013-03-14 2019-06-04 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
AU2014248007B2 (en) 2013-04-05 2020-03-26 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
WO2014169067A1 (en) * 2013-04-09 2014-10-16 Merrimack Pharmaceuticals, Inc. Compositions for improving outcomes of liposomal chemotherapy
EP3071209A4 (en) * 2013-11-19 2017-08-16 The University of Chicago Use of sting agonist as cancer treatment
EP4023765A1 (en) 2013-12-09 2022-07-06 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
ES2800673T3 (es) 2014-08-15 2021-01-04 Myriad Genetics Inc Métodos y materiales para evaluar una deficiencia de recombinación homóloga
EP4141127B1 (en) 2021-08-30 2024-10-09 Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln Method for assessing homologous recombination deficiency in ovarian cancer cells
CN115282140B (zh) * 2022-02-07 2024-03-08 南京市儿童医院 Aki治疗剂及dmxaa在制备该治疗剂中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023753A1 (en) * 1993-04-20 1994-10-27 Cancer Research Campaign Technology Limited Cancer therapy, using antibody conjugates, in combination with a vasoactive agent
US20010027210A1 (en) * 2000-03-03 2001-10-04 Wilson William R. Combination therapy for cancer
WO2002009700A1 (en) * 2000-07-28 2002-02-07 Cancer Research Technology Limited Cancer treatment by combination therapy

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2015265A1 (de) 1969-03-29 1970-10-08 Yoshitomi Pharmaceutical Industries Ltd., Osaka (Japan) Arylalkansäuren und Verfahren zu deren Herstellung
US3655470A (en) * 1969-03-29 1972-04-11 Toa Gosei Chem Ind Process for the production of a foamed thermoplastic resin sheet
US4565806A (en) * 1981-08-18 1986-01-21 Setaelae Kai M E Composition and method for rational treatment of cancer
FR2516922A1 (fr) * 1981-11-25 1983-05-27 Lipha Acides (oxo-4-4h-(1)-benzopyran-8-yl) alcanoiques, sels et derives, preparation et medicament les contenant
DE3587500T2 (de) * 1984-12-04 1993-12-16 Lilly Co Eli Tumorbehandlung bei Säugetieren.
US4704355A (en) * 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
EP0278176B1 (en) 1986-12-23 1994-03-09 Warner-Lambert Company Compounds having antitumour and antibacterial properties
US5281620A (en) * 1986-12-23 1994-01-25 Cancer Research Campaign Technology Limited Compounds having antitumor and antibacterial properties
JPH01193227A (ja) 1988-01-29 1989-08-03 Res Dev Corp Of Japan 癌免疫療法補助剤
US5126129A (en) * 1988-05-23 1992-06-30 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Cancer therapy using interleukin-2 and flavone compounds
US5075287A (en) 1989-03-03 1991-12-24 Nisshin Oil Mills, Inc. Muramyl peptide derivatives and immunoregulating compositions containing them
WO1991004014A1 (en) 1989-09-21 1991-04-04 Synergen, Inc. Method for transporting compositions across the blood brain barrier
US5250296A (en) 1990-11-29 1993-10-05 Takeda Chemical Industries, Ltd. Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
EP0551200A1 (en) 1992-01-07 1993-07-14 National University Of Singapore Protein phosphatase inhibitors for use in therapy
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
GB9320484D0 (en) 1993-10-05 1993-11-24 Wellcome Found Pharmaceutical combinations
DE4417742A1 (de) * 1994-05-20 1995-11-23 Bayer Ag Nicht-systemische Bekämpfung von Parasiten
US5620875A (en) * 1995-02-17 1997-04-15 University Of Portland Transfer of taxol from yew tree cuttings into a culture medium over time
AU5688596A (en) 1995-04-13 1996-10-30 Deutsche Om Arzneimittel Gmbh Anti-cd14 antibodies for use in the induction of il-10 secre tion
WO1996036347A1 (en) 1995-05-17 1996-11-21 Eli Lilly And Company Use of leukotriene antagonists for alzheimer's disease
JPH0940690A (ja) 1995-05-23 1997-02-10 Yutaka Sashita ステロイド配糖体及びこれを有効成分とする医薬
AU6714396A (en) 1995-07-28 1997-02-26 Trustees Of Boston University Methods and compositions for treating cell proliferative disorders
US5977077A (en) 1995-08-28 1999-11-02 Interlab Corporation Xanthone analogs for the treatment of infectious diseases
US5863904A (en) * 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
AU5792398A (en) 1996-12-13 1998-07-03 Eli Lilly And Company Leukotriene antagonists for treatment or inhibition of gout
UA47505C2 (uk) 1996-12-13 2002-07-15 Елі Ліллі Енд Компані Спосіб лікування плоскоклітинного раку ротової порожнини за допомогою антагоністів лейкотриєну
US5817684A (en) * 1996-12-13 1998-10-06 Eli Lilly And Company Leukotriene antagonists for use in the treatment or inhibition of cerebral focal stroke
ES2200316T3 (es) 1997-03-11 2004-03-01 Les Laboratoires Aeterna Inc. Composiciones para tratar tumores que contienen extractos de cartilago de tiburon y agentes antineoplasticos.
WO1998042346A1 (en) 1997-03-21 1998-10-01 Eli Lilly And Company Leukotriene antagonists useful for treating ischemia reperfusion injury
US5998454A (en) 1997-03-21 1999-12-07 Eli Lilly And Company Leukotriene antagonists useful for treating iritis
US5914340A (en) 1997-03-21 1999-06-22 Eli Lilly And Company Leukotriene antagonists useful for treating dermatoses
AU6764798A (en) 1997-03-21 1998-10-20 Eli Lilly And Company Leukotriene antagonists useful for treating cystic fibrosis
WO1998042345A1 (en) 1997-03-21 1998-10-01 Eli Lilly And Company Leukotriene antagonists useful for treating cerebral focal stroke
WO1998042336A1 (en) 1997-03-21 1998-10-01 Eli Lilly And Company Leukotriene antagonists useful for treating gingivitis
AU6450498A (en) 1997-03-21 1998-10-20 Eli Lilly And Company Leukotriene antagonists useful for treating gout
US5910505A (en) * 1997-03-21 1999-06-08 Eli Lilly And Company Leukotriene antagonists for use in the treatment or inhibition of oral squamous cell carcinoma
DE19721211A1 (de) 1997-05-21 1998-11-26 Lindner Sen Wolfgang Dr Med Kombination von antientzündlichen Wirkstoffen mit immunstimulierenden Agentien und zytotoxischen Agentien zur Behandlung von Tumoren
KR20010072957A (ko) 1998-08-24 2001-07-31 추후보정 Ｈ2 수용체 작용제 및 기타 ｔ-세포 활성화제를 사용한ｔ-세포(ｃｄ4+ 및 ｃｄ8+) 활성화 및 보호 방법
CA2343133A1 (en) 1998-09-10 2000-03-23 Magainin Pharmaceuticals, Inc. Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
AUPP609198A0 (en) 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
US6174873B1 (en) * 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
GB9903404D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
PT1033364E (pt) * 1999-03-01 2005-07-29 Pfizer Prod Inc Ciano com acidos oxamicos e derivados como ligandos de receptores de tiroide
JP4638098B2 (ja) * 1999-06-14 2011-02-23 キャンサー・リサーチ・テクノロジー・リミテッド 癌治療
US6806257B1 (en) * 1999-10-20 2004-10-19 Board Of Trustees Of Southern Illinois University Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators
EP1231939A2 (en) 1999-11-11 2002-08-21 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034197A2 (en) 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034137A2 (en) 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034198A2 (en) 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
CA2400197A1 (en) * 2000-02-17 2001-08-23 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
GB0321999D0 (en) * 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations
GT200500186A (es) * 2004-07-07 2006-03-02 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
GB0517387D0 (en) 2005-08-26 2005-10-05 Antisoma Res Ltd Combinations for the treatment of cancer
AU2006283371A1 (en) 2005-08-26 2007-03-01 Antisoma Research Limited Combinations comprising DMXAA for the treatment of cancer
US20100286254A1 (en) 2007-10-23 2010-11-11 Antisoma Research Limited Crystalline forms of dmxaa sodium salt

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023753A1 (en) * 1993-04-20 1994-10-27 Cancer Research Campaign Technology Limited Cancer therapy, using antibody conjugates, in combination with a vasoactive agent
US20010027210A1 (en) * 2000-03-03 2001-10-04 Wilson William R. Combination therapy for cancer
WO2002009700A1 (en) * 2000-07-28 2002-02-07 Cancer Research Technology Limited Cancer treatment by combination therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HILL, S.A.; SAMPSON, L.E.; CHAPLIN, D.A.: "Anti-vascular approaches to solid tumour therapy: Evaluation of vinblastine and flavone acetic acid". INTERNATIONAL JOURNAL OF CANCER, vol. 63, no. 1, 1995, pages 119-123, XP009003224, abstract, page 123, column 2, paragraph 2 *
REWCASTLE, G.W.; ATWELL, G.J.; ZHUANG, L.; BAGULEY, B.C.; DENNY, W.A.: "Potential Antitumour Agents. 61. Structure-Activity Relationships for in Vivo Colon 38 Activity among Disubstituted 9-Oxo-9H-xanthene-4-acetic acids". JOURNAL OF MEDICINAL CHEMISTRY, vol. 34, no. 1, 1991, pages 217-222, XP002226304, cited in the application, abstract *
SIEMANN, D.W.; MERCER, E.; LEPLER, S.; ROJIANI, A.M.: "Vascular targetting Agents Enhance Chemotherapeutic Agent Activities in Solid Tumour Therapy". INTERNATION JOURNAL OF CANCER, vol. 99, 2002, pages 1-6, XP002226322, abstract *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2619335C2 (ru) * 2012-01-20 2017-05-15 Исофол Медикал Аб Тетрагидрофолаты в комбинации с ингибиторами egfr

Also Published As

Publication number Publication date
NZ576925A (en) 2010-07-30
US20040204480A1 (en) 2004-10-14
JP2010270124A (ja) 2010-12-02
CN101596186A (zh) 2009-12-09
EP1423105A2 (en) 2004-06-02
CA2458459A1 (en) 2003-03-13
CY1110426T1 (el) 2015-04-29
US20080070847A1 (en) 2008-03-20
MXPA04002004A (es) 2005-02-17
US20070060637A1 (en) 2007-03-15
EA010857B1 (ru) 2008-12-30
US20080070886A1 (en) 2008-03-20
NZ531045A (en) 2006-08-31
AU2002324143B2 (en) 2007-09-13
DE60230159D1 (de) 2009-01-15
EP1759694A2 (en) 2007-03-07
BR0212258A (pt) 2004-10-19
EP1423105B1 (en) 2008-12-03
US7868039B2 (en) 2011-01-11
EA200801611A1 (ru) 2009-06-30
CN101607087A (zh) 2009-12-23
JP2009263371A (ja) 2009-11-12
EA200601118A1 (ru) 2006-12-29
CN1994287A (zh) 2007-07-11
IS7144A (is) 2004-02-06
GB0121285D0 (en) 2001-10-24
EA200400370A1 (ru) 2004-08-26
WO2003020259A3 (en) 2003-04-17
WO2003020259A2 (en) 2003-03-13
US20080070848A1 (en) 2008-03-20
SI1423105T1 (sl) 2009-08-31
EP1423105B9 (en) 2009-08-12
NZ567456A (en) 2009-08-28
EP2236134A1 (en) 2010-10-06
ES2321283T3 (es) 2009-06-04
NO20040591L (no) 2004-04-30
CN101596187A (zh) 2009-12-09
US20080070849A1 (en) 2008-03-20
US7863322B2 (en) 2011-01-04
NZ554093A (en) 2008-07-31
DK1423105T3 (da) 2009-03-30
EP1759694A3 (en) 2009-02-18
US7863320B2 (en) 2011-01-04
US7868040B2 (en) 2011-01-11
US7863321B2 (en) 2011-01-04
NZ546573A (en) 2007-05-31
ZA200401078B (en) 2005-04-15
ATE415963T1 (de) 2008-12-15
JP2005509599A (ja) 2005-04-14
CN100536840C (zh) 2009-09-09
PT1423105E (pt) 2009-03-09
CN1708296A (zh) 2005-12-14
IL160178A0 (en) 2004-07-25

Similar Documents

Publication Publication Date Title
EA008056B1 (ru) Противораковые комбинации
RU2767664C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
AU2002324143A1 (en) Combinations of dxmaa and other anti-cancer agents
EP1323423B1 (en) Combined preparation comprising a morpholinyl anthracycline derivative and a topoisomerase II inhibitor
AU2007202083B2 (en) Anti-Cancer Combinations
EP1200099A1 (en) Synergistic composition comprising daunorubicin derivatives and antimetabolite compounds
HK1096538A (en) Combined preparations comprising anthracycline derivatives
HK1068786A (en) Combined preparations comprising anthracycline derivatives

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU